Ovarian Cancer

Primary chemotherapy followed by delayed surgery is non-inferior to primary surgery followed by chemotherapy in women with advanced ovarian cancer, with reduced surgical morbidity and mortality.

Neoadjuvant chemotherapy followed by interval debulking surgery is not inferior to primary debulking surgery followed by chemotherapy in patients with bulky stage IIIC or IV ovarian carcinoma. Complete resection of all macroscopic disease remains the objective in cytoreductive surgery.

Completeness of surgical staging is a significant prognostic factor, with better outcomes observed in optimally staged patients. Adjuvant chemotherapy benefits appear restricted to nonoptimally staged patients.

Trabectedin did not improve median OS and demonstrated a worse safety profile compared to physician’s choice chemotherapy.

The addition of HIPEC to interval cytoreductive surgery for stage III epithelial ovarian cancer significantly improves recurrence-free and overall survival without an increase in severe side effects.

Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile

The duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab, and was better tolerated than IP cisplatin.

Weekly dose-dense chemotherapy does not significantly improve progression-free survival compared to standard 3-weekly chemotherapy in a predominantly European population.

Niraparib significantly extends progression-free survival among patients with newly diagnosed advanced ovarian cancer post-response to platinum-based chemotherapy, regardless of homologous-recombination deficiency status.